Related references
Note: Only part of the references are listed.High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance
Annemiek Broyl et al.
BLOOD (2013)
Genome-wide identification of Ikaros targets elucidates its contribution to mouse B-cell lineage specification and pre-B-cell differentiation
Isabel Ferreiros-Vidal et al.
BLOOD (2013)
Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression
Ling-Hua Zhang et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone
Daniel Heintel et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
Jakob Loven et al.
CELL (2013)
Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma
Yuan Xiao Zhu et al.
LEUKEMIA & LYMPHOMA (2013)
RNA-Guided Human Genome Engineering via Cas9
Prashant Mali et al.
SCIENCE (2013)
Multiplex Genome Engineering Using CRISPR/Cas Systems
Le Cong et al.
SCIENCE (2013)
BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia
Christopher J. Ott et al.
BLOOD (2012)
Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma
Yibin Yang et al.
CANCER CELL (2012)
Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
A. Lopez-Girona et al.
LEUKEMIA (2012)
Negative regulators take center stage
Silvia Monticelli et al.
NATURE IMMUNOLOGY (2012)
Aiolos promotes TH17 differentiation by directly silencing Il2 expression
Francisco J. Quintana et al.
NATURE IMMUNOLOGY (2012)
Multiple Myeloma
Jacob Laubach et al.
ANNUAL REVIEW OF MEDICINE, VOL 62, 2011 (2011)
Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
Yuan Xiao Zhu et al.
BLOOD (2011)
Ikaros in immune receptor signaling, lymphocyte differentiation, and function
Matthias Merkenschlager
FEBS LETTERS (2010)
Identification of a Primary Target of Thalidomide Teratogenicity
Takumi Ito et al.
SCIENCE (2010)
Single-vector inducible lentiviral RNAi system for oncology target validation
Dmitri Wiederschain et al.
CELL CYCLE (2009)
Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma
Paul G. Richardson et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
Teresa A. Soucy et al.
NATURE (2009)
Mutation of FOXL2 in Granulosa-Cell Tumors of the Ovary
Sohrab P. Shah et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Global Protein Stability Profiling in Mammalian Cells
Hsueh-Chi Sherry Yen et al.
SCIENCE (2008)
Ikaros DNA-binding proteins as integral components of B cell developmental-stage-specific regulatory circuits
Elizabeth C. Thompson et al.
IMMUNITY (2007)
Lineage dependency and lineage-survival oncogenes in human cancer
Levi A. Garraway et al.
NATURE REVIEWS CANCER (2006)
Mouse model for noninvasive imaging of HIF prolyl hydroxylase activity:: Assessment of an oral agent that stimulates erythropoietin production
M Safran et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Bioluminescent imaging of Cdk2 inhibition in vivo
GJ Zhang et al.
NATURE MEDICINE (2004)
Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein
K Kondo et al.
CANCER CELL (2002)
An intact NEDD8 pathway is required for Cullin-dependent ubiquitylation in mammalian cells
M Ohh et al.
EMBO REPORTS (2002)
Share Paper
